|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Juarez-Hernandez E, Motola-Kuba D,
Chavez-Tapia NC, Uribe M and Barbero Becerra V: Biomarkers in
hepatocellular carcinoma: An overview. Expert Rev Gastroenterol
Hepatol. 11:549–558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yan X, Shao C, Chen C, Chen J, Gu S, Huang
L, Fu X, Zhao H and Qiu Y: Mutation detection of fibroblast growth
factor receptor 3 for infiltrative hepatocellular carcinoma by
whole-exome sequencing. Dig Dis Sci. 62:407–417. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C,
Lv Y, Zhou Z and Liu Z: Hepatocellular carcinoma in a large medical
center of China over a 10-year period: Evolving therapeutic option
and improving survival. Oncotarget. 6:4440–4450. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumari R, Sahu MK, Tripathy A, Uthansingh
K and Behera M: Hepatocellular carcinoma treatment: Hurdles,
advances and prospects. Hepatic Oncol. 5:Hep082018. View Article : Google Scholar
|
|
7
|
Heinrich B, Czauderna C and Marquardt JU:
Immunotherapy of hepatocellular carcinoma. Oncol Res Treat.
41:292–297. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chamovitz DA, Wei N, Osterlund MT, von
Arnim AG, Staub JM, Matsui M and Deng XW: The COP9 complex, a novel
multisubunit nuclear regulator involved in light control of a plant
developmental switch. Cell. 86:115–121. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wei N and Deng XW: COP9: A new genetic
locus involved in light-regulated development and gene expression
in arabidopsis. Plant Cell. 4:1507–1518. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei N and Deng XW: Making sense of the
COP9 signalosome. A regulatory protein complex conserved from
Arabidopsis to human. Trends Genet. 15:98–103. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang H, Ma LG, Li JM, Zhao HY and Deng XW:
Direct interaction of Arabidopsis cryptochromes with COP1 in light
control development. Science. 294:154–158. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwechheimer C and Deng XW: The
COP/DET/FUS proteins-regulators of eukaryotic growth and
development. Semin Cell Dev Biol. 11:495–503. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Richardson KS and Zundel W: The emerging
role of the COP9 signalosome in cancer. Mol Cancer Res. 3:645–653.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee MH, Zhao R, Phan L and Yeung SC: Roles
of COP9 signalosome in cancer. Cell Cycle. 10:3057–3066. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei N and Deng XW: The COP9 Signalosome.
Annu Rev Cell Dev Biol. 19:261–286. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gusmaroli G, Figueroa P, Serino G and Deng
XW: Role of the MPN subunits in COP9 signalosome assembly and
activity, and their regulatory interaction with Arabidopsis
Cullin3-based E3 ligases. Plant Cell. 19:564–581. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Li Y, Wang B, Ma Y and Chen P:
CSN5/Jab1 facilitates non-small cell lung cancer cell growth
through stabilizing survivin. Biochem Biophys Res Commun.
500:132–138. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu H, Hu J, Pan H, Luo D, Huang M and Xu
W: CSN5 promotes hepatocellular carcinoma progression by SCARA5
inhibition through suppressing β-catenin ubiquitination. Dig Dis
Sci. 63:155–165. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao Z, Sang MM, Chen C, Zhu WT, Gong YS
and Pei DS: CSN6 promotes the migration and invasion of cervical
cancer cells by inhibiting autophagic degradation of cathepsin L.
Int J Biol Sci. 15:1310–1324. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi J, Guan X, Zhan F, Liu C, Li Z, Yao Y,
Wang B, Lou C and Zhang Y: CSN6 expression is associated with
pancreatic cancer progression and predicts poor prognosis. Cancer
Biol Ther. 20:1290–1299. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suisse A, Bekes M, Huang TT and Treisman
JE: The COP9 signalosome inhibits Cullin-RING E3 ubiquitin ligases
independently of its deneddylase activity. Fly (Austin).
12:118–126. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schwechheimer C and Deng XW: COP9
signalosome revisited: A novel mediator of protein degradation.
Trends Cell Biol. 11:420–426. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bech-Otschir D, Seeger M and Dubiel W: The
COP9 signalosome: At the interface between signal transduction and
ubiquitin-dependent proteolysis. J Cell Sci. 115:467–473.
2002.PubMed/NCBI
|
|
24
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu M, Zhen L, Lin L, Wu K, Wang Y and Cai
X: Overexpression of CSN6 promotes the epithelial-mesenchymal
transition and predicts poor prognosis in hepatocellular carcinoma.
Clin Res Hepatol Gastroenterol. 44:340–348. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu YS, Tang ZH, Pan QC, Chen XH, Liu XN
and Zang GQ: Inhibition of Csn3 expression induces growth arrest
and apoptosis of hepatocellular carcinoma cells. Cancer Chemother
Pharmacol. 69:1173–1180. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng H, Cheng Y, Guo Z, Zhang F, Lu X,
Feng L, Wang X and Xu Z: Overexpression of CyclinA2 ameliorates
hypoxia-impaired proliferation of cardiomyocytes. Exp Ther Med.
8:1513–1517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gopinathan L, Tan SL, Padmakumar VC,
Coppola V, Tessarollo L and Kaldis P: Loss of Cdk2 and cyclin A2
impairs cell proliferation and tumorigenesis. Cancer Res.
74:3870–3879. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yasmeen A, Berdel WE, Serve H and
Müller-Tidow C: E- and A-type cyclins as markers for cancer
diagnosis and prognosis. Expert Rev Mol Diagn. 3:617–633. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ohashi R, Gao C, Miyazaki M, Hamazaki K,
Tsuji T, Inoue Y, Uemura T, Hirai R, Shimizu N and Namba M:
Enhanced expression of cyclin E and cyclin A in human
hepatocellular carcinomas. Anticancer Res. 21:657–662.
2001.PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fu H, Zhang Y, Chen J, Zhou B, Chen G and
Chen P: Tmub1 suppresses hepatocellular carcinoma by promoting the
Ubiquitination of ΔNp63 isoforms. Mol Ther Oncolytics. 18:126–136.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blanchard JM: Cyclin A2 transcriptional
regulation: Modulation of cell cycle control at the G1/S transition
by peripheral cues. Biochem Pharmacol. 60:1179–1184. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bendris N, Cheung CT, Leong HS, Lewis JD,
Chambers AF, Blanchard JM and Lemmers B: Cyclin A2, a novel
regulator of EMT. Cell Mol Life Sci. 71:4881–4894. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Neureiter D, Stintzing S, Kiesslich T and
Ocker M: Hepatocellular carcinoma: Therapeutic advances in
signaling, epigenetic and immune targets. World J Gastroenterol.
25:3136–3150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen CP: Role of radiotherapy in the
treatment of hepatocellular carcinoma. J Clin Transl Hepatol.
7:183–190. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wicker CA and Izumi T: Analysis of RNA
expression of normal and cancer tissues reveals high correlation of
COP9 gene expression with respiratory chain complex components. BMC
Genomics. 17:9832016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Zheng JN and Pei DS: The emerging
roles of Jab1/CSN5 in cancer. Med Oncol. 33:902016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mao Z, Chen C and Pei DS: The emerging
role of CSN6 in biological behavior and cancer progress. Anticancer
Agents Med Chem. 19:1198–1204. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cheung CT, Bendris N, Paul C, Hamieh A,
Anouar Y, Hahne M, Blanchard JM and Lemmers B: Cyclin A2 modulates
EMT via β-catenin and phospholipase C pathways. Carcinogenesis.
36:914–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Du W, Liu Z, Zhu W, Li T, Zhu Z, Wei L,
Song J and Pei D: CSN6 promotes tumorigenesis of gastric cancer by
ubiquitin-independent proteasomal degradation of
p16INK4a. Cancer Biol Med. 16:514–529. 2019.PubMed/NCBI
|
|
43
|
Schwechheimer C: NEDD8-its role in the
regulation of Cullin-RING ligases. Curr Opin Plant Biol.
45:112–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Su H, Huang W and Wang X: The COP9
signalosome negatively regulates proteasome proteolytic function
and is essential to transcription. Int J Biochem Cell Biol.
41:615–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cavadini S, Fischer ES, Bunker RD, Potenza
A, Lingaraju GM, Goldie KN, Mohamed WI, Faty M, Petzold G, Beckwith
RE, et al: Cullin-RING ubiquitin E3 ligase regulation by the COP9
signalosome. Nature. 531:598–603. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu
Y, Chang SS, Lin WC, Hsu JM, Hsu YH, et al: Deubiquitination and
stabilization of PD-L1 by CSN5. Cancer Cell. 30:925–939. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hou J, Deng Q, Zhou J, Zou J, Zhang Y, Tan
P, Zhang W and Cui H: CSN6 controls the proliferation and
metastasis of glioblastoma by CHIP-mediated degradation of EGFR.
Oncogene. 36:1134–1144. 2017. View Article : Google Scholar : PubMed/NCBI
|
